Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Share, Size [2032]
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Share, Size [2032]
Segments - by Drug Type (Potentiators, Correctors, Combination Drugs, Others), by Route Of Administration (Oral, Inhalation, Others), by Age Group (Pediatric and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
Upcoming
| Report ID :HC-6789
| 4.6 Rating
| 90 Reviews
| 298 Pages
| Format :
Report Description
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Outlook 2032
The cystic fibrosis transmembrane conductance regulator (CFTR) market size was USD 5.8 Billion in 2023 and is projected to reach USD 13.2 Billion by 2032, expanding at a CAGR of 9.6% during 2024–2032.
The demand for orally administered CFTR modulators has seen substantial growth, driven by the effectiveness of these treatments in improving key outcomes such as lung function and nutritional status, and reducing pulmonary exacerbations. The success of oral modulators has not only led to significant revenue generation within the CFTR market but also continued investment in the development of new oral formulations and combination therapies that can address a broader range of CFTR mutations.
Retail pharmacies also play a significant role in patient education and adherence strategies, with pharmacists providing advice on medication management and potential drug interactions. The growth of the segment is supported by the increasing availability of oral CFTR modulators, which are typically easier to handle and store compared to some other formulations, making them ideal for distribution through retail pharmacies.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Dynamics
Drivers
The increasing prevalence of cystic fibrosis across various regions drives the market.For instance,
-
According to the Cystic Fibrosis Foundation, around 105,000 people have been diagnosed with CF across 94 countries.
Cystic fibrosis is a genetic disorder that affects tens of thousands of individuals worldwide, with a notably higher incidence in populations of European descent. The rising diagnosis rates can be attributed to improvements in genetic screening and newborn screening programs, which have become more widespread and sophisticated. This increase in diagnosed cases has naturally led to a heightened demand for effective treatments, thereby driving the growth of the market.
New advances in CFTR research and the development of targeted drug therapies have been crucial in driving the market. Over the past decade, there has been a transformative shift in the treatment landscape of cystic fibrosis, primarily due to the development and approval of CFTR modulators that address the underlying cause of the disease rather than merely its symptoms.
These advancements began with the introduction of the first CFTR potentiator, Ivacaftor, and have since expanded to include a range of other modulators, including combination therapies that can treat a broader spectrum of CFTR mutations. The ongoing investment in research has not only expanded the treatment options available but also deepened the understanding of the molecular mechanisms of the disease, paving the way for next-generation therapies.
Restraints
The high cost of therapies associated with cystic fibrosis transmembrane conductance regulator (CFTR) hinders the market.These therapies are among the most expensive treatments on the market, with annual costs per patient often reaching several hundred thousand dollars. The development of CFTR modulators involves extensive and costly research and development processes, coupled with the complexities of targeting specific genetic mutations, which contribute to their high price tags.
Additionally, the relatively small patient population for CF compared to other diseases does not allow costs to be spread across a large number of individuals, which typically helps to reduce drug prices. The financial burden is often too heavy for many patients and healthcare systems, particularly in countries without comprehensive health insurance coverage or adequate financial assistance programs. This cost barrier limits patient access to these life-changing medications and restricts market growth, as only a fraction of those who could benefit from such treatments can afford them.
Opportunities
The rapid growth of the market in the emerging economies creates new opportunities in the market. Countries in regions such as Asia, Latin America, and parts of Eastern Europe are experiencing rapid economic growth, which in turn leads to enhanced healthcare infrastructure and increased healthcare spending. As these regions invest more in health services, including improved diagnostic facilities and broader healthcare coverage, there is a growing opportunity for the introduction and adoption of advanced CF treatments, including CFTR modulators.
Moreover, the increasing global awareness of cystic fibrosis and its impacts is prompting these markets to develop better screening and diagnostic practices, which can lead to an increase in diagnosed cases. This creates a demand for effective treatments and opens new markets for CFTR therapies that were previously concentrated primarily in North America and Europe. Pharmaceutical companies can capitalize on these emerging markets by establishing partnerships with local healthcare providers, adapting marketing strategies to fit regional needs, and navigating the local regulatory landscapes to facilitate drug approvals and market entry.
Scope of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
|
Attributes |
Details |
|
Report Title |
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2023 |
|
Historic Data |
2017 -2022 |
|
Forecast Period |
2024–2032 |
|
Segmentation |
Drug Type (Potentiators, Correctors, Combination Drugs, and Others), Route of Administration (Oral, Inhalation, and Others), Age Group (Pediatric and Adult), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Vertex Pharmaceuticals; AbbVie Inc. North Chicago, Illinois, U.S.A; F. Hoffmann-La Roche Ltd; Novartis AG; Gilead Sciences, Inc.; Pfizer Inc.; Sanofi S.A.; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Chiesi Farmaceutici S.p.A.; Galapagos NV; Proteostasis Therapeutics, Inc.; ProQR Therapeutics N.V.; Anthera Pharmaceuticals, Inc.; Alaxia SAS; Alcresta Therapeutics, Inc.; Arcturus Therapeutics Holdings Inc.; Translate Bio, Inc.; and Laurent Pharmaceuticals Inc. |
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Segment Insights
Drug Type Segment Analysis
Potentiators segment dominates the cystic fibrosis transmembrane conductance regulator (CFTR) market. The primary mechanism through which potentiators operate involves increasing the probability that the defective CFTR channel opens, thereby improving chloride transport across the cell membrane. This action helps hydrate and clear mucus in the respiratory tract, which is a significant problem for CF patients.
The most notable drug in this category is Ivacaftor, which was the first drug to treat the underlying cause of CF rather than just its symptoms. Since its approval, Ivacaftor has significantly influenced the CFTR market by setting a precedent for the development of gene-specific therapies. The success of Ivacaftor has not only expanded treatment options but also significantly boosted the growth of the segment.
The correctors segment is projected to grow at a significant growth rate during the forecast period. These drugs assist in the proper folding and trafficking of the CFTR protein to the cell surface, addressing the most common mutation found in CF patients, the F508del mutation. Lumacaftor and Tezacaftor are prominent examples of correctors that, when used in combination with potentiators like Ivacaftor, have been shown to improve the amount and function of CFTR proteins on the cell surface, thereby enhancing the chloride transport even further.
The introduction of correctors has substantially broadened the therapeutic landscape of CF, offering hope to a larger pool of patients, especially those with two copies of the F508del mutation. The demand for correctors has seen robust growth, driven by the high prevalence of the F508del mutation among the CF population and the enhanced efficacy of these drugs when used in combination therapies.
Route of Administration Segment Analysis
Oral segment holds a major share of the market, largely due to the systemic nature of cystic fibrosis which affects multiple organs beyond the lungs, including the pancreas and liver. Oral CFTR modulators such as Ivacaftor, Lumacaftor/Ivacaftor combination, and Ivacaftor combination are designed to correct the protein produced by the CF gene so that it can function more effectively. This route of administration is favored for its ease of use, which enhances patient compliance, a critical factor in chronic disease management.
The inhalation segment is projected to experience significant growth in the market, particularly for therapies aimed at managing the pulmonary aspects of cystic fibrosis. This route delivers drugs directly to the lungs, which can be beneficial for targeting the respiratory symptoms of CF, potentially reducing systemic side effects and increasing drug concentration at the site of action.
Inhalation therapies such as inhaled antibiotics are commonly used to manage chronic lung infections associated with CF, but the development of inhaled forms of CFTR modulators is an area of ongoing research. The demand for inhaled therapies is driven by the high burden of lung disease in CF patients and the need for treatments that can effectively manage these complications.
Age Group Segment Analysis
The pediatric segment dominates the market, due to the early onset nature of cystic fibrosis, with most diagnoses occurring in infancy or early childhood. Treating CF in pediatric patients is imperative to manage the progression of the disease and improve long-term outcomes. This segment has seen significant advancements with the approval of CFTR modulators for younger age groups.
The demand for pediatric CFTR therapies is driven by the urgent need to address the genetic root of the disease as early as possible, which can significantly alter the disease's trajectory, potentially reducing the cumulative burden of chronic lung infections and improving growth and nutritional status. The growth of the segment is also influenced by regulatory incentives such as pediatric exclusivity, which extends patent rights, thus encouraging pharmaceutical companies to invest in drug development for children.
The adult segment is projected to grow at a significant growth rate during the forecast period, due to the increasing lifespan of CF patients thanks to advances in treatment. Adults living with cystic fibrosis present a growing demographic needing ongoing and advanced therapeutic solutions. The introduction of combination CFTR modulators has been a game-changer in this segment, offering new hope for improved quality of life and reduced disease progression in adult patients who have experienced years of cumulative lung damage and other complications.
The growth of the segment is characterized by the need for treatments that can offer benefits beyond lung function, including management of diabetes and gastrointestinal issues, which are common in adult CF patients. The approval of drugs for older patients has also broadened the segment, making these therapies accessible to a larger pool of the CF population.
Distribution Channel Segment Analysis
Hospital pharmacies segment holds a major share of the market, particularly due to the specialized nature of cystic fibrosis treatment which often requires coordinated healthcare intervention. This segment is crucial for the initial administration of CFTR therapies, especially when new treatments are introduced and require careful monitoring by medical professionals. Hospital pharmacies are typically located within or near medical facilities, providing immediate access to medications for inpatients and outpatients under direct medical supervision.
This is particularly important for administering more complex or newly released drugs that require additional healthcare provider oversight to manage potential side effects or to adjust dosages optimally. The growth of the segment is driven by the need for integrated care and the high standards of pharmaceutical handling and patient education that hospital settings can provide.
Retail pharmacies segment is anticipated to expand at a robust growth rate during the projection period, offering convenience and accessibility for ongoing, long-term treatment regimens. As patients manage their cystic fibrosis with established CFTR modulators, retail pharmacies provide an accessible means for refilling prescriptions close to home. This segment benefits from the broad geographic spread of outlets, enabling patients from diverse locations to access necessary medications without the need to visit specialist centers or hospitals regularly.
Regional Analysis
North America, particularly the US and Canada, dominates the cystic fibrosis transmembrane conductance regulator (CFTR) market, due to a combination of high disease prevalence, advanced healthcare infrastructure, and substantial investment in healthcare research. The US has one of the highest numbers of cystic fibrosis patients globally, which drives strong demand for CFTR modulators. For instance,
-
According to the American Lung Association, about 30,000 people live with cystic fibrosis in the US.
This region has been at the forefront of CFTR research and drug development, supported by organizations such as the Cystic Fibrosis Foundation, which has been instrumental in funding research and drug development. The regulatory environment in the US, facilitated by the FDA, often leads to earlier drug approvals compared to other regions, making it a critical market for launching new therapies. The market in the region is characterized by high treatment adoption rates, advanced diagnostic facilities, and a well-established healthcare system that collectively drives the growth of the market.
The market in Europe is projected to grow rapidly during the forecast period, with several countries exhibiting strong market dynamics due to high awareness, good healthcare infrastructure, and active government support for healthcare services. Countries such as the UK, Germany, and France have well-established national health services that provide funding and support for cystic fibrosis treatments, including the latest CFTR modulators.
The European Medicines Agency (EMA) plays a crucial role in the approval and regulation of CFTR therapies across Europe, ensuring that safe and effective treatments are available across the continent. The presence of multiple cystic fibrosis registries and research networks in the region aids in the collection of extensive data for research and drug development, further enhancing the growth of the market.
Segments
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market has been segmented on the basis of
Drug Type
- Potentiators
- Correctors
- Combination Drugs
- Others
Route of Administration
- Oral
- Inhalation
- Others
Age Group
- Pediatric
- Adult
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Vertex Pharmaceuticals
- AbbVie Inc. North Chicago, Illinois, U.S.A
- F. Hoffmann-La Roche Ltd
- Novartis AG; Gilead Sciences, Inc.
- Pfizer Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Chiesi Farmaceutici S.p.A.
- Galapagos NV
- Proteostasis Therapeutics, Inc.
- ProQR Therapeutics N.V.
- Anthera Pharmaceuticals, Inc.
- Alaxia SAS
- Alcresta Therapeutics, Inc.
- Arcturus Therapeutics Holdings Inc.
- Translate Bio, Inc
- Laurent Pharmaceuticals Inc.
Competitive Landscape
Key players in the cystic fibrosis transmembrane conductance regulator (CFTR) market are Vertex Pharmaceuticals; AbbVie Inc. North Chicago, Illinois, U.S.A; F. Hoffmann-La Roche Ltd; Novartis AG; Gilead Sciences, Inc.; Pfizer Inc.; Sanofi S.A.; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Chiesi Farmaceutici S.p.A.; Galapagos NV; Proteostasis Therapeutics, Inc.; ProQR Therapeutics N.V.; Anthera Pharmaceuticals, Inc.; Alaxia SAS; Alcresta Therapeutics, Inc.; Arcturus Therapeutics Holdings Inc.; Translate Bio, Inc.; and Laurent Pharmaceuticals Inc.
Recent developments in the CFTR market include the approval of new drug combinations that have demonstrated improved efficacy in treating cystic fibrosis across a wider patient population. For instance,
-
In July 2024, Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to the vanza triple.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size & Forecast, 2023-2032
4.5.1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size and Y-o-Y Growth
4.5.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Absolute $ Opportunity
Chapter 5 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Analysis and Forecast By Drug Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Drug Type
5.1.2 Basis Point Share (BPS) Analysis By Drug Type
5.1.3 Absolute $ Opportunity Assessment By Drug Type
5.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Drug Type
5.2.1 Potentiators
5.2.2 Correctors
5.2.3 Combination Drugs
5.2.4 Others
5.3 Market Attractiveness Analysis By Drug Type
Chapter 6 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Analysis and Forecast By Route Of Administration
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Route Of Administration
6.1.2 Basis Point Share (BPS) Analysis By Route Of Administration
6.1.3 Absolute $ Opportunity Assessment By Route Of Administration
6.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Route Of Administration
6.2.1 Oral
6.2.2 Inhalation
6.2.3 Others
6.3 Market Attractiveness Analysis By Route Of Administration
Chapter 7 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Analysis and Forecast By Age Group
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Age Group
7.1.2 Basis Point Share (BPS) Analysis By Age Group
7.1.3 Absolute $ Opportunity Assessment By Age Group
7.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Age Group
7.2.1 Pediatric and Adult
7.3 Market Attractiveness Analysis By Age Group
Chapter 8 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Analysis and Forecast By Distribution Channel
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
8.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
8.1.3 Absolute $ Opportunity Assessment By Distribution Channel
8.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Distribution Channel
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Online Pharmacies
8.2.4 Others
8.3 Market Attractiveness Analysis By Distribution Channel
Chapter 9 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Region
9.1.2 Basis Point Share (BPS) Analysis By Region
9.1.3 Absolute $ Opportunity Assessment By Region
9.2 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis By Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Analysis and Forecast
11.1 Introduction
11.2 North America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Drug Type
11.6.1 Potentiators
11.6.2 Correctors
11.6.3 Combination Drugs
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis By Drug Type
11.8 Absolute $ Opportunity Assessment By Drug Type
11.9 Market Attractiveness Analysis By Drug Type
11.10 North America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Route Of Administration
11.10.1 Oral
11.10.2 Inhalation
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis By Route Of Administration
11.12 Absolute $ Opportunity Assessment By Route Of Administration
11.13 Market Attractiveness Analysis By Route Of Administration
11.14 North America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Age Group
11.14.1 Pediatric and Adult
11.15 Basis Point Share (BPS) Analysis By Age Group
11.16 Absolute $ Opportunity Assessment By Age Group
11.17 Market Attractiveness Analysis By Age Group
11.18 North America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Distribution Channel
11.18.1 Hospital Pharmacies
11.18.2 Retail Pharmacies
11.18.3 Online Pharmacies
11.18.4 Others
11.19 Basis Point Share (BPS) Analysis By Distribution Channel
11.20 Absolute $ Opportunity Assessment By Distribution Channel
11.21 Market Attractiveness Analysis By Distribution Channel
Chapter 12 Europe Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Analysis and Forecast
12.1 Introduction
12.2 Europe Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Drug Type
12.6.1 Potentiators
12.6.2 Correctors
12.6.3 Combination Drugs
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis By Drug Type
12.8 Absolute $ Opportunity Assessment By Drug Type
12.9 Market Attractiveness Analysis By Drug Type
12.10 Europe Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Route Of Administration
12.10.1 Oral
12.10.2 Inhalation
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis By Route Of Administration
12.12 Absolute $ Opportunity Assessment By Route Of Administration
12.13 Market Attractiveness Analysis By Route Of Administration
12.14 Europe Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Age Group
12.14.1 Pediatric and Adult
12.15 Basis Point Share (BPS) Analysis By Age Group
12.16 Absolute $ Opportunity Assessment By Age Group
12.17 Market Attractiveness Analysis By Age Group
12.18 Europe Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Distribution Channel
12.18.1 Hospital Pharmacies
12.18.2 Retail Pharmacies
12.18.3 Online Pharmacies
12.18.4 Others
12.19 Basis Point Share (BPS) Analysis By Distribution Channel
12.20 Absolute $ Opportunity Assessment By Distribution Channel
12.21 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Asia Pacific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Drug Type
13.6.1 Potentiators
13.6.2 Correctors
13.6.3 Combination Drugs
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis By Drug Type
13.8 Absolute $ Opportunity Assessment By Drug Type
13.9 Market Attractiveness Analysis By Drug Type
13.10 Asia Pacific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Route Of Administration
13.10.1 Oral
13.10.2 Inhalation
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis By Route Of Administration
13.12 Absolute $ Opportunity Assessment By Route Of Administration
13.13 Market Attractiveness Analysis By Route Of Administration
13.14 Asia Pacific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Age Group
13.14.1 Pediatric and Adult
13.15 Basis Point Share (BPS) Analysis By Age Group
13.16 Absolute $ Opportunity Assessment By Age Group
13.17 Market Attractiveness Analysis By Age Group
13.18 Asia Pacific Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Distribution Channel
13.18.1 Hospital Pharmacies
13.18.2 Retail Pharmacies
13.18.3 Online Pharmacies
13.18.4 Others
13.19 Basis Point Share (BPS) Analysis By Distribution Channel
13.20 Absolute $ Opportunity Assessment By Distribution Channel
13.21 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Latin America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Analysis and Forecast
14.1 Introduction
14.2 Latin America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Drug Type
14.6.1 Potentiators
14.6.2 Correctors
14.6.3 Combination Drugs
14.6.4 Others
14.7 Basis Point Share (BPS) Analysis By Drug Type
14.8 Absolute $ Opportunity Assessment By Drug Type
14.9 Market Attractiveness Analysis By Drug Type
14.10 Latin America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Route Of Administration
14.10.1 Oral
14.10.2 Inhalation
14.10.3 Others
14.11 Basis Point Share (BPS) Analysis By Route Of Administration
14.12 Absolute $ Opportunity Assessment By Route Of Administration
14.13 Market Attractiveness Analysis By Route Of Administration
14.14 Latin America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Age Group
14.14.1 Pediatric and Adult
14.15 Basis Point Share (BPS) Analysis By Age Group
14.16 Absolute $ Opportunity Assessment By Age Group
14.17 Market Attractiveness Analysis By Age Group
14.18 Latin America Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Distribution Channel
14.18.1 Hospital Pharmacies
14.18.2 Retail Pharmacies
14.18.3 Online Pharmacies
14.18.4 Others
14.19 Basis Point Share (BPS) Analysis By Distribution Channel
14.20 Absolute $ Opportunity Assessment By Distribution Channel
14.21 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Middle East & Africa (MEA) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Drug Type
15.6.1 Potentiators
15.6.2 Correctors
15.6.3 Combination Drugs
15.6.4 Others
15.7 Basis Point Share (BPS) Analysis By Drug Type
15.8 Absolute $ Opportunity Assessment By Drug Type
15.9 Market Attractiveness Analysis By Drug Type
15.10 Middle East & Africa (MEA) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Route Of Administration
15.10.1 Oral
15.10.2 Inhalation
15.10.3 Others
15.11 Basis Point Share (BPS) Analysis By Route Of Administration
15.12 Absolute $ Opportunity Assessment By Route Of Administration
15.13 Market Attractiveness Analysis By Route Of Administration
15.14 Middle East & Africa (MEA) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Age Group
15.14.1 Pediatric and Adult
15.15 Basis Point Share (BPS) Analysis By Age Group
15.16 Absolute $ Opportunity Assessment By Age Group
15.17 Market Attractiveness Analysis By Age Group
15.18 Middle East & Africa (MEA) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Size Forecast By Distribution Channel
15.18.1 Hospital Pharmacies
15.18.2 Retail Pharmacies
15.18.3 Online Pharmacies
15.18.4 Others
15.19 Basis Point Share (BPS) Analysis By Distribution Channel
15.20 Absolute $ Opportunity Assessment By Distribution Channel
15.21 Market Attractiveness Analysis By Distribution Channel
Chapter 16 Competition Landscape
16.1 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market: Competitive Dashboard
16.2 Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market: Market Share Analysis, 2023
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Vertex Pharmaceuticals AbbVie Inc. North Chicago, Illinois, U.S.A F. Hoffmann-La Roche Ltd Novartis AG; Gilead Sciences, Inc. Pfizer Inc. Sanofi S.A. GlaxoSmithKline plc Teva Pharmaceutical Industries Ltd. Mylan N.V. Chiesi Farmaceutici S.p.A. Galapagos NV Proteostasis Therapeutics, Inc. ProQR Therapeutics N.V. Anthera Pharmaceuticals, Inc. Alaxia SAS Alcresta Therapeutics, Inc. Arcturus Therapeutics Holdings Inc. Translate Bio, Inc Laurent Pharmaceuticals Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
